Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person* McGeorge Anne			D	2. Issuer Name and Ticker or Trading Symbol Dianthus Therapeutics, Inc. /DE/ [DNTH]						(Che	eck all applic	r	10% Ov	vner			
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024								below)	(give title	Other (: below)	specify	
C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
													X Form filed by One Reporting Person Form filed by More than One Reporting				
(Street) NEW YO	ORK N	Y	10036	L									Persor		lan One Nepo	rung	
				R	ule	10b5-	1(c)	Transa	ction	ı Indi	ication						
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			. Transaction Date Month/Day/Y	Execution Date,		Code (Instr. 5)			d (A) or tr. 3, 4 and	5. Amou Securitie Beneficia Owned F Reported	es For ially (D) Following (I) (I	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	/ An	mount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Dat if any (Month/Day/Ye	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expir Date	ration	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$21.77	05/23/2024		A		11,000		(1)	05/22	2/2034	Common Stock	11,000	\$0	11,000	D		

1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

/s/ Adam Veness, as attorneyin-fact for Anne McGeorge

** Signature of Reporting Person

05/28/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.